Kornimate/medical-research-clean huggingface dataset:
sunitinib and atrial trabeculae contractility

Conditions: Cardiotoxicity; Ischemia; Heart Failure

Summary: rationale: recently, sunitinib (a tyrosine kinase inhibitor that is used for treatment of metastatic renal carcinoma and gastrointestinal stroma tumors) has been associated with development of heart failure, possibly by off-target inhibition of amp-protein kinase. the investigators hypothesize that sunitinib reduces the contractile ability of myocardium and the tolerance against ischemia-reperfusion and that activators of amp-protein kinase such as atorvastatin and aicar reverse this unwanted effect of sunitinib. objectives: the primary objective of the study is to investigate the effect of sunitinib on ex-vivo atrial contractile force in absence and presence of ischemia-reperfusion. a secondary objective is to explore if atorvastatin or aicar prevent sunitinib-induced deterioration of contractile function of human atrial trabeculas. study design: lab

study population: 44 (+22) patients undergoing cabg cardiac surgery with extracorporal circulation intervention (if applicable): none (pharmacological interventions will only be performed ex-vivo in isolated atrial tissue) main study parameters/endpoints the developed force in ex vivo atrial trabeculas during standardized stimulation.

Eligibility criteria:
inclusion criteria: * cardiac surgery with extracorporal circulation exclusion criteria: * use of oral antiarrhythmics * theophylline use * use of sulfonylureas * atrial arrythmias * right ventricular failure
effect of hearing aid labeling on speech understanding measures

Conditions: Hearing Loss

Summary: new and experienced hearing aid users will be fit with two hearing devices. one will be labeled as an otc (over-the-counter) device, the other will be labeled as a prescriptive (i.e. professionally fit) device. both devices will be generically programmed for a mild to moderate hearing loss. an objective speech in noise test will be completed with both devices.


Eligibility criteria:
inclusion criteria: * adults age 18 or older with bilateral mild to moderate hearing loss * experienced users must have at least 6 months hearing aid experience * new users must have no prior hearing aid experience, defined as never owning their own devices exclusion criteria: * self-reported ear related pathology (otorrhea w/in 90 days, dizziness, sudden hearing loss or worsening of hearing w/in 90 days, otalgia) * visible deformity of the ear * chronic, severe tinnitus * unilateral hearing loss * cognitive impairment
ultrasound-guided vascular puncture and catheterization

Conditions: Vascular Access Complication; Ultrasound Therapy; Complications; Perioperative/Postoperative Complications; Cardiovascular Abnormalities

Summary: to assess and improve the safety and success rate of vascular puncture and catheterization using ultrasound-guided methods.

investigators hypothesized that （1） various ultrasound-guided methods had different performances of vascular puncture and catheterization, (2) certain risk factors influenced safety and success rate of vascular puncture and catheterization (3) implementation of protocols could improve the performances of ultrasound-guided vascular puncture and catheterization.

Eligibility criteria:
inclusion criteria: * age above 18 years old. * scheduled for selective surgery. * requirement of perioperative vascular puncture and catheterization. * american standard of anesthesia level i-iv. exclusion criteria: * contraindication to vascular puncture or catheterization. * occlusion or thrombosis of target vessel evaluated by ultrasound. * refuse or disagreement from participants.

Keywords: vascular access vascular catheterization ultrasound-guided ultrasonography perioperative anesthesia cardiovascular abnormalities
standard chemotherapy plus moxifloxacin as first-line treatment for metastatic triple-negative breast cancer

Conditions: Triple Negative Breast Cancer

Summary: the primary objective of this study is to compare progression-free survival (pfs) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.

this is a multicenter, randomised, double-blind, placebo-controlled, phase 3 trial. the main purposes of this study are to examine the efficacy and safety of standard chemotherapy plus moxifloxacin or placebo as first-line treatment in patients with metastatic triple-negative breast cancer. this study is designed to recruit up to 228 subjects.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) score of 0 to 1. * histologically confirmed invasive ductal carcinoma, no specific type (nos) * er negative and progesterone receptor (pr) negative (defined as \< 1% positive cells by ihc), human epidermal growth factor receptor 2 (her2) negative (defined as ihc 0-1 staining or fluorescent in situ hybridization (fish) negative). * no prior therapy after first recurrence or diagnosis of metastatic disease. * at least 1 measurable lesion as defined by response evaluation criteria in solid tumors (recist) criteria. * neutrophil-to-lymphocyte ratios (nlr) in peripheral blood ≥ 2. * adequate organ function including bone marrow, renal function, hepatic function, and cardiac reserve (left ventricular ejection fraction (lvef) by echocardiogram ≥45%). * compliance with the study protocol. * have provided written and signed informed consent. exclusion criteria: * pregnant or breast feeding. * definitive breast cancer susceptibility gene (brca) mutation, programmed cell death-ligand 1 (pd-l1) positive, microsatellite instability-high (msi-h), and mismatch repair deficient (dmmr). * patients who are receiving or will receive other biological agents or immunotherapy. * uncontrolled medical problems. * evidence of active acute or chronic infection. * hepatic, renal, cardiac, or bone marrow dysfunction as detailed above. * concurrent malignancy or history of other malignancy within the last five years. * known severe hypersensitivity to moxifloxacin * patients were unable or unwilling to comply with program requirements.
donors predisposed by corneal collagen cross-linking in deep lamellar keratoplasty for the patients with keratoconus

Conditions: Keratoconus

Summary: the study was designed as a randomized controlled study with the following objectives: to investigate whether use of donors predisposed by corneal collagen cross-linking (cxl) reduced myopic refractive errors for keratoconic eyes after deep anterior lamellar keratoplasty (dalk). overall 70 patients are planned to recruit., the patients were assigned to cxl graft group, in which corneal donors predisposed by cxl were used, or the conventional graft group, in which corneal donors stored in corneal storage media were used. the patients will be followed-up for 24 months.

keratoconus is a progressive ecstatic corneal disease characterized by forward bulging of the cornea, thinning of the corneal stroma, and irregular astigmatism. corneal transplantation is necessary for patients with advanced keratoconus when spectacles and contact lens are inadequate for visual correction. deep anterior lamellar keratoplasty is a conventional procedure for the treatment of keratoconus. however, dalk itself frequently causes abnormality of refraction, such as high degrees of astigmatism owing to irregular corneal surface for keratoconic eyes. possible mechanisms of this progressive astigmatism include the recurrence of keratoconus in the grafts, progressive corneal thinning of the host cornea, or progressive misalignment of the graft- host interface over time, which prevents the achievement of satisfactory vision. corneal collagen cross-linking is believed to have the ability to halt or decrease the progression of keratoconus. cxl treats keratoconus by strengthening corneal stromal collagen bonds with riboflavin activated by ultraviolet a (uva), and is now a first-line treatment for progressive keratoconus. in this randomized controlled trial, we performed cxl on corneal donor tissues with the aim of achieving corneal stromal stiffening, thereafter dalk was conducted for the patients with advanced keratoconus using the tissues predisposed by cxl. the goal of this study is evaluating whether the strengthening grafts could reduce postoperative myopic refractive errors or arrest the progression of keratoconus for the patients with dalk.

Eligibility criteria:
inclusion criteria: * 1.the best corrected visual quality of frame glasses is less than 0.3，2.the best corrected visual quality of rigid gas permeable contact lens (rgpcl) is less than 0.5/ rgpcl intolerance，3.the anterior corneal surface curvature \>55d，4.the thinnest corneal thickness is less than 400 μm. one of the above four items is met * patients must be willing and able to return for scheduled follow-up examinations for 36 months after surgery * ages：over 18 years exclusion criteria: * history of intraocular surgery * severe dry eye * severe eyelid and conjunctival scar * loss of vision in contralateral eye * pregnant and lactating women

Keywords: corneal collagen cross-linking deep lamellar keratoplasty keratoconus
clinical and radiographic success following regenerative pulpotomy using chitosan hydrogel versus platelet rich fibrin in mature mandibular molars

Conditions: Regenerative Pulpotomy for Symptomatic Pulpitis of Mandibular Permanent Molars With Mature Apices

Summary: the aim of this study is to assess the clinical and radiographic success and postoperative pain in mature mandibular molars following vital pulp therapy using chitosan hydrogel versus platelet rich fibrin.


Eligibility criteria:
inclusion criteria: * patients suffering from symptomatic pulpitis in mature mandibular molars only will be involved. * tooth should give positive response to cold test * haemostasis should be achieved after full pulpotomy * the tooth is restorable and free from advanced periodontal disease, cracks and splits. * patients should be free from any systemic disease that may affect normal healing and predictable outcome. * patients who will agree to the consent and will commit to follow-up period. * patients with mature root apices * patients with no internal or external resorption and no periapical lesions * soft tissues around the tooth are normal with no swelling or sinus tract exclusion criteria: * patients with immature roots. * haemostasias after 10 minutes cannot be controlled after full pulpotomy patients with any systemic disease that may affect normal healing. * patients with periapical lesions or infections. * pregnant females. * patients who could/would not participate in a 6 months follow-up. * patients with fistula or swelling * patients with necrotic pulp. * patients with old age.
the effect of intercostal nerve block with dexamethasone and ropivacaine on rebound pain after thoracoscopic surgery

Conditions: Rebound Pain; Dexamethasone; Intercostal Nerve Block; Thoracoscopic Surgery

Summary: regional nerve block is one of the commonly used methods for postoperative analgesia after thoracoscopic surgery. recent studies have found that rebound pain may occur after regional block, which is defined as acute postoperative pain that occurs after the resolution of sensory block related to regional anesthesia, and seriously affects the quality of postoperative recovery of patients. there is evidence that rebound tenderness is associated with local anesthetic toxicity and proinflammatory effects. the aim of this study was to investigate the effect of dexamethasone on rebound pain after a single intercostal nerve block in patients undergoing thoracoscopic surgery.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective thoracoscopic surgery age \> 18 years old asa ⅰ-ⅲ informed consent was signed exclusion criteria: * patients with aoagulation disorders patients with allergy to local anesthetics patients with severe cardiopulmonary diseases patients had systemic steroid use patients with chronic pain patients with uncontrolled diabetes and mental disorders history of drug abuse; body mass index more than 35 kg.m-2 pregnant or breastfeeding woman.
sub omohyoid suprascapular nerve block versus interscalene nerve block

Conditions: Post Operative Pain; Regional Anesthesia; Nerve Block

Summary: shoulder surgery can be very painful surgery after which the use of opioids is often required. the well-known side-effects of opioids (e.g. respiratory depression, somnolence, nausea, vomiting, and pruritus) limit their use in so called 'fast track' surgery and anaesthesia programmes. the study aimed to compare the effect of sub omohyoid suprascapular nerve block versus interscalene nerve block in preventing postoperative pain and decreasing analgesic consumption in patients scheduled for shoulder surgery


Eligibility criteria:
inclusion criteria: 1. aged 18-60 years. 2. asa i-ii. 3. both sexes. 4. shoulder surgery. exclusion criteria: 1. patient refusal 2. allergy to local anesthetics 3. bmi \>40 kg/m2 4. bleeding diathesis or history of anticoagulant use. 5. psychiatric diseases. 6. infection of the skin at the site of needle punctures area.

Keywords: interscalene brachial plexus block shoulder pain subomohyoid plane block
yoga and occupational therapy to improve pain

Conditions: Chronic Pain

Summary: this was a randomized control trial of a yoga and self-management intervention for individuals with chronic pain. participants were assigned to either a wait-list control group (self-management only), or a yoga intervention (self-management and yoga). self-management education session occurred monthly within the community. group yoga intervention was delivered two times a week with a specifically designed program that was progressively more difficult. assessments were then administered pre and post intervention, and a semi-structured interview was completed following the intervention. quantitative and qualitative data were then compared between groups.

this was a randomized control trial completed with two specific aims. aim 1: to assess the feasibility of completing a group yoga intervention in conjunction with an ongoing self-management education for people with chronic pain. aim 2: to explore the preliminary efficacy of a group yoga intervention in people with chronic pain. the key variables of interest were pain interference, functional performance, balance, strength, mobility, and quality of life (qol)

Eligibility criteria:
inclusion criteria: * greater than 18 years of age * individual with self-reported pain for over six months * attending outpatient pain clinic * ability to attend yoga classes * ability to complete assessments * ability to provide informed consent exclusion criteria: * consistent yoga practice over the past year * self-reported exercise restrictions * serious and recent medical procedures or conditions without doctor's note * high risk pregnancy

Keywords: yoga chronic pain occupational therapy self-management
comparative effects of myofascial arm pull technique and post isometric relaxation on pain, range of motion and functional disability in adhesive capsulitis after mastectomy

Conditions: Adhesive Capsulitis

Summary: adhesive capsulitis (ac) also known as frozen shoulder typically manifests to decrease range of motion (rom) and function and increase pain in shoulder .objective of the study is to compare the effects of myofascial arm pull technique and post-isometric relaxation on pain, range of motion and functional disability in adhesive capsulitis after mastectomy. the study design will be a randomized clinical trial that will be used to compare the effects of myofascial arm pull technique with post isometric relaxation. subject with adhesive capsulitis meeting the predetermined inclusion \& exclusion criteria will be divided into two groups. pre assessment will be done using numeric pain rating scale nprs for pain , shoulder pain and disability index (spadi) tool for disability and goniometer for range of motion. consent will be taken from patients by consent form the patients. they will be divided into two groups randomly by random number generator table: group a and group b. for common treatment, both the groups will receive ultrasound with a dosage of 1 mhz in frequency, continuous mode and 1.5 w/ cm2 of intensity for 10 minutes of treatment duration and movement with mobilization will be applied for 15 times in 3 sets, and a 1- minute rest period was provided between each set. group a will be given post isometric relaxation technique with ultrasonic therapy. group b will be given myofascial arm pull technique with ultrasonic. total intervention protocol will be given for four weeks of duration 3 sessions per week with total 12 sessions. in post isometric relaxation technique the therapist will slowly provide resistance in the direction of flexion, abduction, or external rotation, and without the subject intending to move for 15 minutes/ day, 3 times/week for 12 weeks. similarly, myofascial arm pull technique the therapist will hold arm of the subject firmly and initial stretch will be applied in abduction and external rotation for 8-10 times in each session per day for 3 days/week for 4 weeks. outcome measures will be measured at baseline, after 2 weeks and after 4 weeks. data analysis will be done by spss version 25.


Eligibility criteria:
inclusion criteria: * only female gender * age between 25 to 50 years with post mastectomy. * diagnosis of breast cancer (grade 1to3 b). * post mastectomy state at least 6 months. * shoulder pain that began after the breast cancer surgery exclusion criteria: * bilateral breast cancer. * history of neurologic deficits affecting shoulder functioning during daily activites. * on numeric pain rating scale pain will be less than 5.
study to investigate benefits of weight loss in young adults and adolescents

Conditions: Obesity; Insulin Resistance

Summary: the purpose of this study is to investigate the changes in subcutaneous adipocyte size, number and gene expression after weight loss and to assess whether those changes contribute to decreases in ectopic fat accumulation and insulin resistance in women between ages of 16-32.

there are no studies in young women that have prospectively studied changes in fat cell size, gene expression and insulin sensitivity during the transition from overweight/obese to normal weight. our preliminary data suggest that the presence of ectopic fat accumulation and insulin resistance in obese children could be considered an "early phase" in the development of t2dm. we hypothesize that a 10% weight loss will restore/improve insulin sensitivity. furthermore, we speculate that the decrease in subcutaneous fat mass after weight loss is due to a decrease in mean adipocyte cell size, but not cell number.

Eligibility criteria:
inclusion criteria: * women ages 16-32 exclusion criteria: * they will not be on any medications that are known to alter glucose or insulin metabolism, such as oral steroids, or certain psychiatric medications, such as xeleca, lithium and paxil. patients on diuretics will be excluded.

Keywords: obesity insulin resistance weight loss women
efficacy and safety of canadá association in the treatment of chronic pain

Conditions: Pain, Chronic

Summary: the purpose of this study is to evaluate the efficacy and safety of canadá association in the treatment of chronic pain


Eligibility criteria:
inclusion criteria: * ability to confirm voluntary participation and agree to all trial purposes by signing and dating the consent form; * chronic pain during at least 3 months. exclusion criteria: * any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of participants; * history of alcohol abuse or illicit drug use; * participation in a clinical trial in the year prior to this study; * pregnancy or risk of pregnacy and lactating participants; * known hypersensitivity to any of the formula compounds.

Keywords: analgesia pain management
single high-dose brachytherapy for giant osteosarcoma masses

Conditions: Osteosarcoma

Summary: this study is a prospective, single-arm, phase ii, single-center study. patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10gy of implantable brachytherapy. record treatment-related acute events during and after treatment. follow up on survival and local control after treatment ends, marking the end of the trial treatment.

screening period: local mri or ct examination, blood routine and coagulation function test. selected treatment period: all enrolled patients received one dose of close range interstitial radiotherapy with a radiation dose of 10 gy. the number of insertion needles depends on the size and location of the tumor. the instrument used for radiotherapy is the medda high-dose rate brachytherapy machine, and the radiation source is 192 iridium. record treatment related acute events such as bleeding during the treatment period. follow up: follow up with local mri or ct at 1 month, 3 months, 6 months, and 1 year after the end of radiotherapy treatment to evaluate the treatment effect; simultaneously follow up with patients for survival and treatment related adverse reactions, such as dermatitis, infections, etc.

Eligibility criteria:
inclusion criteria: 1. pathological diagnosis of osteosarcoma; 2. age range 12-70 years old; 3. the primary or metastatic lesion cannot be surgically removed based on clinical evaluation, and treatment with internal medicine multi line chemotherapy, targeted therapy, immunotherapy, etc. is ineffective; 4. ecog physical fitness status is 0-1 points; 5. according to recist version 1.1 standard, there must be at least one evaluable target lesion with a mass length diameter greater than 5cm; 6. sign a written informed consent form before conducting any experimental activities; 7. researchers determine that they are able to comply with the research protocol; 8. patients who are willing and able to comply with visit arrangements, treatment plans, laboratory tests, and other research procedures. exclusion criteria: 1. local mass previously received radiation therapy; 2. major surgery ≤ 4 weeks before enrollment; 3. previous or concurrent malignant tumors (excluding malignant tumors that have been cured and have a cancer free survival of more than 5 years, such as basal cell carcinoma of the skin and papillary thyroid carcinoma); 4. pregnant or lactating women; 5. active pulmonary tuberculosis.

Keywords: brachytherapy high-dose osteosarcoma